Socioeconomic Status and Cervical Cancer Survival Among Older Women: Findings from the SEER-Medicare Linked Data Cohorts
Overview
Affiliations
Objectives: Tumor stage, age, and cell type are well-characterized predictors for cervical cancer survival; socioeconomic factors may also play an important role. The purpose of this study is to estimate cervical cancer survival by socioeconomic indicators and race/ethnicity among elderly women diagnosed with cervical cancer.
Methods: We studied 1251 women with cervical cancer aged 65 or older, identified between 1992 and 1999 from the Surveillance, Epidemiology, and End Results [SEER]-Medicare linked data. All women had similar access to care through Medicare fee-for-services insurance. A composite measure of socioeconomic status was created using census tract level data for poverty, education, and income. Cox proportional hazard modeling was used for all-cause and cervical cancer-specific survival analysis.
Results: Increased age (P < 0.0001) and advanced tumor stage (<0.0001) were associated with poorer all-cause and cervical cancer-specific survival. After adjustment for age, stage, and treatment, increased co-morbidity scores and having non-squamous cervical cancer were associated with poorer all-cause survival (P < 0.001). After adjusting for confounders, women receiving hysterectomy vs. no surgery or any treatment had significantly better all-cause and cervical cancer-specific survival. Socioeconomic factors were not associated with either all-cause (P for trend = 0.79) or cervical cancer-specific (P for trend = 0.81) survival. No racial/ethnic differences in all-cause or cervical cancer-specific survival were observed after adjusting for socioeconomic factors.
Conclusion: Among women with similar access to care, neither minority race/ethnicity nor poorer socioeconomic status were associated with poorer survival in this large sample of older women diagnosed with invasive cervical cancer. Presence of co-morbid conditions and treatment were important predictors of cervical cancer survival.
Jeevarajan S, Harikrishnan P, Balamurugan T, Arunachalam A J Obstet Gynaecol India. 2023; 73(5):414-420.
PMID: 37916048 PMC: 10616017. DOI: 10.1007/s13224-023-01843-y.
Shou H, Wan Q, Xu H, Shi L, Song T BMC Womens Health. 2023; 23(1):270.
PMID: 37198594 PMC: 10193738. DOI: 10.1186/s12905-023-02427-8.
Lichter K, Levinson K, Hammer A, Lippitt M, Rositch A Gynecol Oncol. 2022; 165(1):67-74.
PMID: 35115179 PMC: 8969176. DOI: 10.1016/j.ygyno.2022.01.017.
Compaore Z, Monnet E, Gerazime A, Molinie F, Guizard A, Delafosse P Cancer Causes Control. 2022; 33(3):403-415.
PMID: 35079925 DOI: 10.1007/s10552-021-01536-9.
Quick A, Krok-Schoen J, Stephens J, Fisher J Cancer Control. 2020; 27(1):1073274820979590.
PMID: 33291971 PMC: 8480352. DOI: 10.1177/1073274820979590.